ESMO Reaction
September 15, 2022

ESMO Reactions: TROPiCS-2

ESMO Reaction
September 15, 2022

ESMO Reactions: TROPiCS-2

Author

Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) inpatients with HR+/HER2- metastatic breast cancer.

Abstract #LBA76: Hope Rugo presented interim OS results from the P3 TROPiCS-02 trial, which compared sacituzumabgovitecan (SG) (n=272) vs physician’s choice (n=271) in heavily pre-treated HR+/HER2- endocrine-resistant, unresectable locally advanced or metastatic breast cancer.

Results: SGdemonstrated significant improvement in OS (median: 14.4 vs 11.2 months for TPC),and significant improvement in objective response rate (21% vs 14%) and quality of life.

Thought leader reactions were moderately positive, with several welcoming any OS benefit in a population with limited treatment options. Comparisons to recent PFS data were positive:

However, some questioned the importance ofan overall survival benefit of only three months:

Several commentators hope and expect FDA approval for sacituzumab govitecan in this population:

One KOL would like to know the impact of this data on Trop-2 negative breast cancer patients and wonders why Trop-2 expression was not assessed.

Summary:

This interim analysis of TROPiCS-2 OS data represents a positive step for this small population with limited treatment options. Some, however, consider the data only “incremental” or “modest”instead of game changing. Still, thought leaders expect FDA approval for sacituzumabgovite can in this population.

Synthesis by Opus Strategy, LLC

Download attached file

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.